APA (7th ed.) Citation

de Latour, R. P., Szer, J., Weitz, I. C., Röth, A., Höchsmann, B., Panse, J., . . . Hillmen, P. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. The Lancet. Haematology, 9(9), e648. https://doi.org/10.1016/S2352-3026(22)00210-1

Chicago Style (17th ed.) Citation

de Latour, Régis Peffault, et al. "Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria (PEGASUS): 48-week Follow-up of a Randomised, Open-label, Phase 3, Active-comparator, Controlled Trial." The Lancet. Haematology 9, no. 9 (2022): e648. https://doi.org/10.1016/S2352-3026(22)00210-1.

MLA (9th ed.) Citation

de Latour, Régis Peffault, et al. "Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria (PEGASUS): 48-week Follow-up of a Randomised, Open-label, Phase 3, Active-comparator, Controlled Trial." The Lancet. Haematology, vol. 9, no. 9, 2022, p. e648, https://doi.org/10.1016/S2352-3026(22)00210-1.